je.st
news
Tag: incyte
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
2017-01-09 14:00:47| Merck.com - Product News
Dateline City: WILMINGTON, D.E. & KENILWORTH, N.J. Additional pivotal studies evaluating Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, D.E. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incytes investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Language: English read more
Tags: with
development
program
combination
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda (pembrolizumab) as First-line Treatment for Advanced Melanoma
2015-10-13 13:30:03| Merck.com - Product News
Dateline City: WILMINGTON, Del. and KENILWORTH, N.J. Pivotal study to evaluate Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incytes investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Mercks anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Language: English read more
Tags: for
advanced
include
study
Eli Lilly, Incyte drug fares well in late-stage research
2015-09-29 16:11:28| Biotech - Topix.net
A potential rheumatoid arthritis treatment from Eli Lilly and Incyte fared better than another drug in late-stage testing, and the drugmakers are moving closer to seeking regulatory approval to sell it. Lilly said Tuesday that early results from a study that enrolled around 600 patients showed that its oral medication, baricitinib, proved superior to the established treatment methotrexate.
Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
2015-09-02 08:04:11| drugdiscoveryonline News Articles
Incyte Corporation recently announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody
Tags: global
agreement
license
medicine
Incyte Corporation Moves Up In Market Cap Rank, Passing Cabot Oil & Gas
2014-12-31 13:21:18| Oil & Gas - Topix.net
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock.
Tags: market
corporation
rank
gas